Skip to main content
Premium Trial:

Request an Annual Quote

Myriad, DaVita Team on Protein Marker Research

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its Myriad RBM subsidiary has formed a research collaboration with DaVita Labs to discover protein-based biomarkers that could be used to benefit dialysis patients.

The firms said that the primary focus of the collaboration will be on markers that predict vascular access failure.

DaVita Labs, a unit of DaVita HealthCare Partners, will provide specimens from its biorepository, while Myriad RBM will use its DiscoveryMAP platform to analyze the samples for potential use as biomarkers. Myriad expects to begin processing specimens for the collaboration in its fiscal year 2014, which begins July 1.

"We have extensive experience with research in kidney disease and inflammatory markers that we believe could increase the quality of care for dialysis patients," Craig Benson, president of Myriad RBM, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.